13F Holdings
中文EN

NMTC NEUROONE MEDICAL TECHNOLOGIES Corp

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1500198 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY42.8%
TTM net income YoY-39.5%
TTM EPS YoY-20.9%
Revenue 3-yr CAGR94.9%
Net income 3-yr CAGR—

Margins

Gross margin55.6%
Operating margin-83.4%
Net margin-78.6%
FCF margin-75.6%
EBITDA margin-81.0%

Returns

ROE-124.7%
ROA-87.6%
ROIC (approx.)-671.9%
Asset turnover1.11x

Leverage & solvency

Liabilities / assets39.1%
Debt / equity0.00x
Current ratio2.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-09-30FY20242024-09-30FY20232023-09-30FY20222022-09-30FY20212021-09-30
Income statement
Revenue$9.10M$3.45M$1.95M$171,169$178,146
Cost of revenue$3.96M$2.37M$1.50M$241,963$275,895
Gross profit$5.14M$1.08M$456,517-$70,794-$97,749
R&D expense$4.98M$5.07M$6.94M$4.93M$3.93M
SG&A expense$7.38M$7.90M$6.93M$6.98M$6.26M
Operating income-$4.23M-$11.89M-$11.96M-$10.03M-$10.22M
Interest expense————$3,053
Pretax income-$3.61M-$12.32M-$11.86M-$10.00M—
Income tax————-$271,122
Net income-$3.61M-$12.32M-$11.86M-$10.00M-$9.95M
EBITDA-$3.96M-$11.64M-$11.76M-$9.91M-$10.14M
EPS (basic)-0.09-0.46-0.65-0.63-0.93
EPS (diluted)-0.09-0.46-0.65-0.63-0.93
Weighted avg. shares (diluted)40.15M26.76M18.12M16.00M10.70M
Banking
Net interest income————-$3,053
Balance sheet
Cash & equivalents$6.57M$1.46M$5.32M$8.16M$6.90M
Short-term investments———$2.98M—
Receivables$1.26M$176,636—$33,237$48,336
Inventory$2.23M$2.64M$1.73M$704,538$98,287
Current assets$10.23M$4.63M$7.31M$12.18M$7.29M
PP&E, net$259,222$416,843$525,753$353,599$223,329
Intangibles$44,946$67,262$89,577$111,892$134,207
Total assets$10.79M$5.37M$8.10M$12.82M$7.94M
Current liabilities$2.30M$2.21M$1.79M$3.10M$1.18M
Short-term debt——$129,116——
Long-term debt——$55,284$119,556$202,895
Total debt——$184,400$119,556$202,895
Total liabilities$3.71M$4.55M$1.85M$3.22M$1.38M
Shareholders' equity$7.07M$822,013$6.25M$9.60M$6.55M
Net debt——-$5.14M-$8.04M-$6.70M
Shares outstanding8.33M30.82M23.93M16.22M12.01M
Cash flow statement
Operating cash flow-$2.84M-$11.01M-$12.89M-$7.52M-$8.60M
Capital expenditure$81,742$120,197$384,117$275,226$67,079
Free cash flow-$2.92M-$11.13M-$13.27M-$7.79M-$8.67M
Investing cash flow-$81,742-$120,197$2.65M-$3.24M-$67,079
Financing cash flow$8.03M$7.27M$7.40M$12.02M$11.53M
Depreciation & amortization$261,679$246,791$199,266$118,620$80,748
Stock-based compensation$1.26M$1.34M$1.11M$947,212$1.79M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.